Concepedia

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

Preetesh Jain, Hagop M. Kantarjian, Elias Jabbour, Graciela Nogueras González, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Evguenia Gachimova, Alessandra Ferrajoli, Steven M. Kornblau,

The Lancet Haematology · 2015 · 106 citations · 38 references

DOIFull text

Open access

Concepts

References

38

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.6K citations · Full text

, , +10

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

, , +9

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

Risto Kerkelä, Luanda Grazette, Rinat Yacobi et al. · Nature Medicine · 2006 · 1.2K citations

, , +10

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

, , +17

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, Hagop M. Kantarjian, Neil P. Shah et al. · New England Journal of Medicine · 2012 · 770 citations · Full text

, , +13